29 research outputs found

    Search for the decay K+ to pi+ gamma gamma in the pi+ momentum region P>213 MeV/c

    Full text link
    We have searched for the K+ to pi+ gamma gamma decay in the kinematic region with pi+ momentum close to the end point. No events were observed, and the 90% confidence-level upper limit on the partial branching ratio was obtained, B(K+ to pi+ gamma gamma, P>213 MeV/c) < 8.3 x 10-9 under the assumption of chiral perturbation theory including next-to-leading order ``unitarity'' corrections. The same data were used to determine an upper limit on the K+ to pi+ gamma branching ratio of 2.3 x 10-9 at the 90% confidence level.Comment: 15 pages, 3 figures; no change in the results, accepted for publication in Physics Letters

    Rare KK Decays

    Get PDF
    The rare decays of the KK meson have had a long tradition as a laboratory for testing the symmetry properties of the weak interactions, and the manner in which these symmetries are broken by higher order effects. Present--day interest is focussed on decays that are suppressed by CPCP--symmetry or GIM symmetry. Such decays, in the standard theory, are sensitive to effects of the virtual top quark, and could also reveal new interactions transcending the standard model. In addition, the radiative decays of the KK meson have become a useful testing--ground for effective Lagrangians describing the low energy interactions of pions, kaons and photons.Comment: Invited Talk at the Third Workshop on High Energy Particle Physics (WHEPP 3) Madras, 1994, LaTex, 14 pages, 3 figures available upon reques

    Search for electroweak production of single top quarks in ppˉp\bar{p} collisions.

    Get PDF
    We present a search for electroweak production of single top quarks in the electron+jets and muon+jets decay channels. The measurements use ~90 pb^-1 of data from Run 1 of the Fermilab Tevatron collider, collected at 1.8 TeV with the DZero detector between 1992 and 1995. We use events that include a tagging muon, implying the presence of a b jet, to set an upper limit at the 95% confidence level on the cross section for the s-channel process ppbar->tb+X of 39 pb. The upper limit for the t-channel process ppbar->tqb+X is 58 pb. (arXiv

    Univariate Distribution Relationships

    No full text

    Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial

    Get PDF
    Background Venous thromboembolism (VTE) is a frequent cardiovascular disease with severe complications, including recurrence and death. There is a great need for alternative prophylactic treatment options as anticoagulation is accompanied by increased bleeding risk. Statins are reported to reduce the risk of incident and recurrent VTE, but the mechanisms are elusive. Procoagulant phospholipids (PPL), and phosphatidylserine in particular, are crucial for efficient coagulation activation, but no studies have investigated the effect of statin treatment on plasma PPL activity. Objectives To investigate the impact of rosuvastatin treatment on plasma PPL activity and levels of extracellular vesicles (EVs). Patients/Methods Patients with a history of VTE (>= 18 years) allowed to stop anticoagulant treatment were randomized to either 20 mg/day of rosuvastatin treatment or no treatment for 28 days in the Statins Reduce Thrombophilia (NCT01613794) trial. Plasma samples were collected at baseline and study end. PPL activity was measured in samples from 245 participants using a factor Xa-dependent clotting assay and EV levels by flow cytometry. Results Rosuvastatin treatment yielded an overall 22% (95% confidence interval [CI] -38.2 to -5.8) reduction in PPL activity, and 37% (95% CI -62.9 to -11.2) reduction in PPL activity in participants with a history of pulmonary embolism. The effect of rosuvastatin on plasma PPL activity was not explained by changes in total cholesterol nor change in levels of total- or platelet-derived EVs. Conclusions Rosuvastatin treatment caused a substantial decrease in plasma PPL activity, suggesting that a PPL-dependent attenuation of coagulation activation may contribute to a reduced VTE risk following statin treatment.Clinical epidemiolog
    corecore